Suzhou Fengbei Biotech Stock Co., Ltd. (SHA:603334)
China · Delayed Price · Currency is CNY 54.75
+1.23 (2.30%)
Feb 13, 2026, 3:00 PM CST
SHA:603334 Revenue
Suzhou Fengbei Biotech Stock had revenue of 773.28M CNY in the quarter ending September 30, 2025, with 56.55% growth. This brings the company's revenue in the last twelve months to 2.81B. In the year 2024, Suzhou Fengbei Biotech Stock had annual revenue of 1.95B with 12.75% growth.
Revenue (ttm)
2.81B
Revenue Growth
+12.75%
P/S Ratio
2.79
Revenue / Employee
8.18M
Employees
344
Market Cap
7.86B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.95B | 220.23M | 12.75% |
| Dec 31, 2023 | 1.73B | 19.09M | 1.12% |
| Dec 31, 2022 | 1.71B | 413.11M | 31.89% |
| Dec 31, 2021 | 1.30B | 505.78M | 64.04% |
| Dec 31, 2020 | 789.81M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Anhui Huaheng Biotechnology | 2.83B |
| Nanjing Vazyme Biotech | 1.34B |
| Shenzhen Weiguang Biological Products | 1.14B |
| Wuhan Keqian Biology Co.,Ltd | 1.01B |
| Jiangxi Fushine Pharmaceutical | 970.32M |
| Acrobiosystems | 794.52M |
| GemPharmatech | 793.25M |
| R&G PharmaStudies | 789.45M |